The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of
lung cancers has raised significant clinical interest because small molecule inhibitors may …

The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of
lung cancers has raised significant clinical interest because small molecule inhibitors may …

Introduction The detection of a ROS1 rearrangement in advanced and metastatic lung
adenocarcinoma (LUAD) led to a targeted treatment with tyrosine kinase inhibitors with …

Background ROS1 rearrangement is an oncogenic driver of non-small cell lung cancer
(NSCLC). Accurate detection of ROS1 rearrangements in clinical tumor samples is vital. In …

ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer
and is associated with slight/never smoking patients and adenocarcinoma histology …

Background ROS1 gene fusions cause several cancers by constitutively activating the ROS1
tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the …

Introduction The ROS1 gene rearrangement has become an important biomarker in NSCLC.
The College of American Pathologists/International Association for the Study of Lung …

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor,
crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the …

e21733 Background: ROS1 rearrangement occurs in approximately 1%-2% of non-small
cell lung cancer, and it is predictive of treatment response to tyrosine kinase inhibitor. The …

Introduction Translocations of the ROS1 gene were found to drive tumorigenesis in 1% to
2% of lung adenocarcinoma. In clinical practice, ROS1 rearrangements are often screened …